Viscardi, R. M., Othman, A. A., Hassan, H. E., Eddington, N. D., Abebe, E., Terrin, M. L., . . . Waites, K. B. (2013). Azithromycin To Prevent Bronchopulmonary Dysplasia in Ureaplasma-Infected Preterm Infants: Pharmacokinetics, Safety, Microbial Response, and Clinical Outcomes with a 20-Milligram-per-Kilogram Single Intravenous Dose. American Society for Microbiology.
Citação norma ChicagoViscardi, Rose M., Ahmed A. Othman, Hazem E. Hassan, Natalie D. Eddington, Elias Abebe, Michael L. Terrin, David A. Kaufman, and Ken B. Waites. Azithromycin To Prevent Bronchopulmonary Dysplasia in Ureaplasma-Infected Preterm Infants: Pharmacokinetics, Safety, Microbial Response, and Clinical Outcomes With a 20-Milligram-per-Kilogram Single Intravenous Dose. American Society for Microbiology, 2013.
Citação norma MLAViscardi, Rose M., et al. Azithromycin To Prevent Bronchopulmonary Dysplasia in Ureaplasma-Infected Preterm Infants: Pharmacokinetics, Safety, Microbial Response, and Clinical Outcomes With a 20-Milligram-per-Kilogram Single Intravenous Dose. American Society for Microbiology, 2013.